Adult stem cell transplantation combined with conventional therapy for the treatment of end-stage liver disease: a systematic review and meta-analysis

Table 1 Clinical information from the eligible trials in the meta-analysis

First authors/published year	Country	No. of patients		Therapeutic regimen		Cell source	Cell dosage
First authors/published year	Country	Con	Exp	Con	Exp	Cell source	Cell dosage
Cai et al. 2015	China	28	23	Conventional medical treatment	Conventional medical treatment and G-CSF CD34⁺ APBSC transplantation	G-CSF CD34⁺ APBSC	(2.0–4.0) × 10^7
Liu et al. 2014	China	37	40	Lamivudine and adefovir dipivoxil	G-CSF ABMMSC transplantation in combination with lamivudine and adefovir dipivoxil	G-CSF ABMMSC	(1.6–3.2) × 10^11
Bai et al. 2014	China	15	32	Routine medical treatment	Treated with BM-MNCs plus a conventional internal medicine regimen	BM-MNCs	NA
Al Tayeb et al. 2015	Egypt	10	10	Conventional therapy	Conventional therapy and the G-CSF PB-MNCs transplantation	G-CSF PB-MNCs	NA
Deng et al. 2015	China	35	33	Conventional medical therapy	Conventional medical therapy and G-CSF CD34⁺ APBSC transplantation	G-CSF CD34⁺ APBSC	(2.0–4.0) × 10^7
Fang et al. 2018	China	53	50	Normal medical treatments	Normal medical treatments with the transplantation of hUCMSCs at twice	hUCMSCs	(4.0–4.5) × 10^8
Peng et al. 2011	China	105	53	Conventional medical therapy	Conventional medical therapy and ABMMSC transplantation	ABMMSC	1.0 × 10^7
Suk et al. 2016	Korea	18	Exp1:18 Exp2:19	Treatment-guideline for AC	Exp1: treatment-guideline for AC and one-time ABMMSC transplantation Exp2: treatment-guideline for AC and two-time ABMMSC transplantation	ABMMSC	5.0 × 10^7

First authors/published year	Age (mean ± SD) (years)		Sex (M/F)		Study design	Disease etiology		Injection route	Times of injection	Length of follow-up (months)
First authors/published year	Con	Exp	Con	Exp	Study design	Con	Exp	Injection route	Times of injection	Length of follow-up (months)
Cai et al. 2015	50.82 ± 7.98	51.52 ± 10.30	17/11	14/9	nRCT	HBV	HBV	Hepatic artery	Single	12
Liu et al. 2014	50.4 ± 8.5	51.6 ± 9.2	33/4	37/3	RCT	HBV	HBV	Left and right hepatic arteries	Single	1
Bai et al. 2014	47.4 ± 11.1	46.4 ± 11.6	9/6	20/12	nRCT	HBV:13 AC: 2	HBV:30 AC: 2	Hepatic artery	Single	24
Al Tayeb et al. 2015	49.20 ± 3.27	49.20 ± 3.27	10/0	10/0	nRCT	HCV	HCV	Hepatic artery	Single	6
Deng et al. 2015	50.20 ± 10.64	49.48 ± 11.07	12/23	20/13	RCT	HBV	HBV	Hepatic artery	Single	12
Fang et al. 2018	46.55 ± 9.08	46.62 ± 10.17	49/4	45/5	RCT	HBV	HBV	Vein	Twice	13
Peng et al. 2011	42.22 ± 11.37	42.19 ± 10.80	99/6	50/3	nRCT	HBV	HBV	Proper hepatic artery	Single	48
Suk et al. 2016	53.7 ± 8.2	Exp1:53.1 ± 8.7 Exp2:54.4 ± 7.9	17/1	Exp1:15/3 Exp2:17/2	RCT	AC	AC	Hepatic artery	Exp1:single Exp2: twice	12

APBSCs, autologous peripheral blood stem cells; BM-MNCs, bone marrow mononuclear cells; hUCMSCs, human umbilical cord mesenchymal stem cells; ABMMSC, autologous bone marrow mesenchymal stromal cells; PB-MNCs, peripheral blood mononuclear cells; AC, alcoholic cirrhosis; nRCT, non-randomized control trial; RCT, randomized control trial; HBV, hepatitis B virus; HCV, hepatitis C virus; NA, not available; G-CSF, granulocyte colony-stimulating factor